ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BIOA vs LYEL // GROSS PROFIT MARGIN

BioAge Labs Inc. (NASDAQ) VS. Lyell Immunopharma Inc. (NASDAQ) • 15-METRIC TALLY: BIOA 0 — LYEL 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIOA VS. LYEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BIOA LYEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) — -41.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.66 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 LYEL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.4 61.4 -18.03 LYEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $272.6M $277.0M -$4.4M LYEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BIOA REV LYEL REV BIOA GROSS % LYEL GROSS % BIOA FCF LYEL FCF
FY 2025 $9.0M $36.0K — — -$82.3M -$150.8M
FY 2024 $0 $61.0K — — -$51.9M -$162.9M
FY 2023 $0 $130.0K — — -$37.4M -$163.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIOA // BETA —
LYEL // BETA —